Adding abiraterone to standard treatment improves prostate cancer survival by 40 per cent
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate cancer presented at the 2017 ASCO Annual Meeting (link is external) in Chicago. The results from the Cancer Research UK-funded STAMPEDE trial […]